|
Diagnosis:
Chronic Lymphocytic Leukemia |
|
Chronic Lymphocytic
Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
The Key Features |
-
Small cells with
pseudofollicles;
-
Positive: CD5 and CD23
-
Negative or weak: CD20,
CD22, CD79b, CD11c
-
Negative: CD10, FMC7,
Cyclin D1
-
Worse prognosis:
germline IgVH, CD38+, ZAP70+, trisomy 12, deletions
at 11q22-23
-
Better prognosis:
mutated IgVH, deletions at 13q14
|
|
|
CLINICAL FEATURES |
-
CLL is the most common leukemia in
the Western world and comprises 90% of chronic lymphoid
leukemias; SLL/CLL accounts for 6.7% of NHL;
-
Age: most patients>50 years, median
65 years; M:F=2:1;
-
CLL: lymphocyte count in bone
marrow and peripheral blood >5×109/L, possible <5×109/L
provided typical morphology and immunoprofile;
-
SLL: absence of bone marrow or
blood involvement;
-
Clinical features: most patients
asymptomatic, or fatigue, infection, autoimmune hemolytic
anemia, hepatosplenomegaly, lymphadenopathy, or extranodal
involvement.
|
|
MICROSCOPIC FINDINGS |
-
Lymph node and spleen
-
Architecture: effacement of the
lymph node with a pseudofollicular pattern;
occasionally intrafollicular infiltrate; In the spleen,
white pulp is often prominently involved and also red pulp;
-
Pseudofollicules: pale areas
containing a continuum of small, medium and larger cells in
dark background of small cells; prolymphocytes: medium size,
nuclei with dispersed chromatin and small nucleoli; para-immunoblasts:
medium to large size, round to oval nuclei with dispersed
chromatin and central eosinophilic nucleoli and slightly
basophilic cytoplasm;
-
Cytology: predominantly small
cells, slightly larger than normal lymphocytes; round nuclei
with clumped chromatin and occasional a small nucleolus; low
mitotic activity; in some cases, the small lymphoid cells
show moderated nuclear irregularity, resembling MCL;
occasionally, tumor cells may present plasmacytoid
differentiation.
-
Bone marrow and blood
-
Small cells, clumped chromatin,
and scant clear to basophilic cytoplasm, nucleoli indistinct
or absent, frequent smudge cells and basket cells;
-
Prolymphocytes usually <2%; CLL
with increased prolymphocytes, 10%<prolymphocytes<50%;
-
Bone marrow involvement may be
nodular, interstitial, diffuse or combined; paratrabecular
aggregates are not typical;
-
Some CLL cases may show atypical
morphology with variable proportional atypical lymphocytes
(cleaved cells, prolymphocytes and large lymphocytes) with
characteristic CLL immunophenotype;
-
Richter syndrome: transformation to
DLBCL (3.0% of CLL) is characterized by confluent sheets of
large cells that paraimmunoblasts or immunoblast-like; or
transformation into Hodgkin lymphoma (0.5% of CLL).
|
|
SUBTYPES |
-
CLL of naive B-cell origin: 40-50%,
no somatic mutations of IgVH;
-
CLL of post-germinal center B-cell
origin: 50-60%, with somatic mutation of IgVH, better survival.
|
|
DIFFERENTIAL DIAGNOSES |
| |
CLL/SLL |
B-PLL |
HCL |
SMZL |
FL |
MCL |
|
sIg |
+
(dim) |
+ |
+ |
+ |
+ |
+ |
|
CD19 |
+ |
+ |
+ |
+ |
+ |
+ |
|
CD20 |
+
(dim) |
+ |
+ |
+ |
+ |
+ |
|
CD22 |
− |
+ |
+ |
+ |
+ |
+ |
|
FMC7 |
− |
+ |
+ |
+ |
+ |
+ |
|
CD79b |
− |
+ |
+ |
+ |
+ |
+ |
|
CD5 |
+ |
− |
− |
− |
− |
+ |
|
CD23 |
+ |
+/− |
− |
− |
+/− |
− |
|
CD25 |
+/− |
− |
+ |
− |
− |
− |
|
CD11c |
+/− |
− |
+ |
+/− |
− |
− |
|
CD103 |
− |
− |
+ |
− |
− |
− |
|
CD10 |
− |
− |
− |
− |
+ |
− |
|
|
IMMUNOHISTOCHEMISTRY
AND SPECIAL STAINS |
-
Positive: weak or dim surface IgM
or IgM and IgD, CD5, CD19, CD20 (weak), CD22 (weak), CD79a,
CD23, CD43, CD11c (weak);
-
Negative: CD10, cyclin D1, FMC7 and
CD79b
|
|
CYTOGENETIC STUDIES |
-
Trisomy 12: 20%, aggressive
clinical course;
-
Deletions at 13q14: 50%, long
survival;
-
Deletions at 11q22-23: 20%, poor
survival
|
|
TREATMENT AND
PROGNOSIS |
-
Indolent, median survival of CLL 7
years, and median survival of SLL 5 years;
-
CD38+ and/or ZAP70+ cases, worse
prognosis;
|
|
REFERENCES |
- Practical Diagnosis of
Hematologic Disorders, Fourth Edition. By Carl R. Kjeldsberg,
2006.
-
Jaffe ES, Harris
NL, Stein H, Vardiman JW, editors. Pathology and genetics of tumours of
haematopoietic and lymphoid tissues. World Health Organization classification of
tumours. Lyon (France): IARC Press; 2001.
|